(73), conducted a retrospective analysis to evaluate the efficacy of a lymphodepletion regimen consisting of decitabine (DAC), fludarabine (Flu), and cyclophosphamide (Cy) prior to CD19/CD22 bispecific CAR-T therapy in R/R B-ALL patients. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.